Bringing dd-cfDNA testing to your own laboratory
One workflow. Reliable results.
dd-cfDNA Overview
Donor-derived cell-free DNA (dd-cfDNA) is used as a biomarker to assess organ health and rejection risk status
dd-cfDNA has a very short half life (30 minutes – 2 hours) and elevations can be detected almost immediately1
The use of dd-cfDNA as a tool for transplant monitoring is well established in over 60 publications across multiple transplant types
GraftAssure TM is a dd-cfDNA test that uses droplet digital PCR (dPCR) technology to measure the concentration of dd-cfDNA using 48 predefined SNPs with high minor allele population frequency. The kit enables the determination of both fractional (%) and absolute (copies/mL) concentration of dd-cfDNA for a comprehensive understanding of the amount of dd-cfDNA in the sample.
Highlights & Advantages of GraftAssure
One workflow for any sample
Generate dd-cfDNA results using both fractional abundance (%)
and absolute concentration (cp/mL)
In-house testing generates quick results
dPCR is a cost-effective way to quantify dd-cfDNA
Low sample input volume required
Conduct high quality research on dd-cfDNA applications in your own lab
Average hands-on time < 30 minutes
Simple and Consistent Workflow
Centrifuge blood tubes and collect plasma
30 minutes*
DNA extraction
20 minutes
Preamplification
40 minutes
Digital PCR
3-7 hours
Results available
4-8 hours*
Kit Specifications
- Up to 24 samples may be analyzed per kit
- All kit components are lyophilized to maximize reagent stability and enable easy transportation and storage of materials
Interested in purchasing GraftAssure?
| GraftAssure | Components in Kit | Quantity |
|---|---|---|
| Reagents | Allele-Specific dd-PCR Reagents | 24 Sets |
| Preamplification Reagents | 1 Vial | |
| Total Quantification ddPCR Reagents | 1 Vial |
For Research Use Only.
Not for use in diagnostic procedures.
We’re here to help
Oncocyte Customer Service can answer any questions you have.
Please contact us at:
Phone: 844-621-8880
Email: [email protected]
REFERENCES 1. Oellerich M, Sherwood K, Keown P, et al. (2021). Liquid biopsies: donor-derived cell-free DNA for the detection of kidney allograft injury. Nat Rev Nephrol 17(9):591.
© 2024 Oncocyte Corporation. All Rights Reserved. Oncocyte and GraftAssure are trademarks of Oncocyte Corporation. All other trademarks are the property of their respective owners. For the intended uses of GraftAssure and other products, please refer to www.oncocyte.com.